U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07014449) titled 'Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia' on May 22.
Brief Summary: The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia (R/R AML). The main questions it aims to answer are:
* What is the safety and tolerability profile of WBC100 in R/R AML patients?
* Can WBC100 effectively induce remission in R/R AML patients?
Participants will:
* Take WBC100 capsules orally once daily in 28-day treatment cycles;
* Undergo regular safety assessments, includi...